Related Experiment Video
Updated: Jun 29, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Update on FDG-PET in pediatric lymphoma
1Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany - lars.kurch@medizin.uni-leipzig.de.
Insights
Fluorodeoxyglucose-positron emission tomography (FDG-PET) is crucial for staging and assessing chemotherapy response in pediatric Hodgkin lymphoma. Its role in pediatric non-Hodgkin lymphoma is currently limited but holds future potential for treatment management.
Area of Science:
- Pediatric oncology
- Nuclear medicine
- Medical imaging
Background:
- Lymphoma is the third most common childhood malignancy, categorized into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL).
- P-HL treatment combines chemotherapy and radiotherapy, with FDG-PET integral for over 20 years in staging and response assessment.
- P-NHL is primarily treated with chemotherapy, where FDG-PET's current role is subordinate.
Purpose of the Study:
- To present the current status of FDG-PET in pediatric lymphoma management.
- To detail the application of FDG-PET in staging and response assessment for pediatric lymphomas.
- To discuss challenges, pitfalls, and future directions of FDG-PET in pediatric lymphoma.
Main Methods:
- Review of current literature and clinical practice regarding FDG-PET use in pediatric lymphoma.
- Analysis of FDG-PET's role in staging and response assessment for both P-HL and P-NHL.
- Discussion of existing challenges and future potential of FDG-PET in pediatric lymphoma treatment.
Main Results:
- FDG-PET is well-established and integral in P-HL for staging and chemotherapy response assessment, guiding treatment intensity.
- FDG-PET plays a subordinate role in P-NHL treatment, with its potential for management largely underutilized.
- Key aspects covered include staging, response assessment, challenges, and future developments of FDG-PET in pediatric lymphoma.
Conclusions:
- FDG-PET is essential for optimizing P-HL treatment through precise staging and response evaluation.
- Significant untapped potential exists for FDG-PET to enhance P-NHL treatment strategies.
- Further research and integration are needed to fully leverage FDG-PET's capabilities in pediatric lymphoma care.
Abstract:
Lymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy alone. At present FDG-PET plays only a subordinate role in the treatment setting. Its potential to contribute to treatment management is far from being fully utilised. In this article, the current status of FDG-PET in pediatric lymphoma is presented in detail. The core elements are the sections on staging and response assessment. In addition, challenges and pitfalls are discussed and future developments are outlined.
